Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Part D Prior Auth Coverage Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Prior Authorization Requirements — Specialty & Part D Drugs

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, exclusions, prescriber and duration rules for Medicare Part D prescription drugs on the HealthPartners formulary; affects prescribers and pharmacists submitting Part D PA requests for affected products.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Prior Authorization Requirements — Specialty & Part D Drugs
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required diagnostic or genetic testing results, and documentation of prior therapy trials or contraindications as specified for the requested Part D drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20+distinct products listed
    12 monthscommon renewal duration
    6 monthscommon initial durations
    FID: 26132formulary reference
    Multiplespecialist prescriber required

    Coverage Criteria — Product-specific Requirements

    Abiraterone: Initial Therapy

    Covered when ALL of the following are met:

    Abiraterone initial approval: (1) Diagnosis of an FDA‑approved indication for abiraterone (e.g., metastatic high‑risk castration‑sensitive prostate cancer or metastatic castration‑resistant prostate cancer) that is not excluded from Part D; (2) Genetic testing completed, if required, with results indicating the requested agent is appropriate; (3) Patient does not have an FDA‑labeled limitation of use or contraindication to abiraterone that is not otherwise supported in NCCN guidance; (4) The requested agent is FDA‑labeled or supported by compendia for the requested indication, OR the patient is currently receiving or previously received and benefited from abiraterone; (5) Requested dosing is within FDA‑labeled dosing guidelines (provide rationale if 500 mg tablet requested instead of 250 mg).

    Renewal requires documented positive response to therapy; initial coverage duration six months.

    Actemra: Initial Therapy

    Covered when ALL of the following are met:

    Actemra initial approval: (1) Diagnosis of a listed FDA‑approved indication (examples: rheumatoid arthritis with inadequate response or contraindication to at least two preferred drugs; polyarticular juvenile idiopathic arthritis after inadequate response to two preferred drugs; giant cell arteritis after inadequate response to at least one preferred drug; systemic juvenile idiopathic arthritis; systemic sclerosis‑associated ILD after inadequate response to mycophenolate) and the indication is not excluded from Part D; (2) Documented inadequate response or medical contraindication to the required number of preferred agents per indication; (3) Prescribed by or in consultation with an appropriate specialist (e.g., rheumatologist or pulmonologist); (4) Not used concurrently with another biologic therapy; (5) Dosing limited to FDA‑labeled dosing.
    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Prior Authorization Requirements — Specialty & Part D Drugs
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required diagnostic or genetic testing results, and documentation of prior therapy trials or contraindications as specified for the requested Part D drug.
    SourceLink
    On This Page
    Coverage Criteria — Product-specific RequirementsInitial Therapy — Entry RequirementsRenewal and Continuation — Evidence of BenefitStep Therapy / Prerequisite TrialsFormulary and Product CodingProvider Actions — Prior Authorization & DocumentationQuantity and Dosing LimitsSite-of-Care Determinations (Part B vs Part D)Clinical Definitions and Diagnostic ThresholdsBackground and ScopeRevision History

    Coverage duration 12 months

    Adempas: Initial Therapy

    Covered when ALL of the following are met:

    Adempas initial approval for Group 1 PAH: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For Group 1 pulmonary arterial hypertension (PAH): diagnosis confirmed by right heart catheterization showing mean pulmonary artery pressure (mPAP) ≥20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >2 Wood units; (3) Prescribed by or in consultation with a cardiologist or pulmonologist; (4) Not used concurrently with nitrates, nitric oxide donors, phosphodiesterase inhibitors, or non‑specific PDE inhibitors; (5) Limited to FDA‑labeled dosing.mPAP >=20 mmHg; PCWP <=15 mmHg; PVR >2 Wood units

    Coverage duration 12 months

    Testosterone products: Initial Therapy

    Covered when ALL of the following are met:

    Testosterone replacement initial approval: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Documented serum testosterone deficiency with level <300 ng/dL prior to initiation (except where alternate indication-specific rules apply, e.g., delayed puberty or metastatic breast cancer where enanthate may be approved); (3) Prescribed for an appropriate indication and limited to FDA‑labeled dosing; (4) Patient must not have an FDA‑labeled limitation of use or contraindication to testosterone therapy.serum testosterone <300 ng/dL

    Coverage duration 12 months

    Armodafinil — Initial/renewal

    Covered when ALL of the following are met for initial therapy:

    Armodafinil initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND one of the following indication‑specific confirmations: (A) Obstructive sleep apnea (OSA) diagnosed by sleep study with ≥15 obstructive respiratory events/hour, or ≥5 events/hour plus at least one listed symptom when sleep study performed or prescriber documents study not feasible; OR (B) Shift‑work disorder with supporting sleep study demonstrating circadian disruption and no other condition/medication explaining symptoms; OR (C) Narcolepsy confirmed by polysomnography and multiple sleep latency testing unless prescriber documents study not feasible; OR (D) Adjunctive therapy for bipolar depression when patient has intolerance or contraindication to at least two antidepressants from different classes. (2) Not used concurrently with another target agent such as modafinil. (3) Dosing limited to FDA‑labeled dosing.OSA thresholds as specified; see node text

    Initial coverage six months; renewal requires documented positive response and then coverage may be extended to 12 months.

    ATTRUBY — Initial/renewal

    Covered when ALL of the following are met for initial therapy:

    ATTRUBY initial criteria: (1) Diagnosis of wild‑type or hereditary transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM) not excluded from Part D; (2) Diagnostic confirmation by either (A) cardiac biopsy with positive Congo red staining and ATTR confirmation by mass spectrometry or immunofluorescence, OR (B) exclusion of monoclonal protein (serum free light chain ratio within reference range and negative serum and urine immunofixation) plus myocardial uptake on 99mTc‑PYP with heart‑to‑contralateral ratio >1.5 or visual grade ≥2; (3) Clinical history consistent with heart failure (prior HF hospitalization or symptomatic cardiomyopathy) and NYHA class I–III; (4) Negative for light‑chain amyloidosis; (5) Prescribed by or in consultation with a cardiologist; (6) Dosing limited to FDA labeling; (7) Renewal requires prescriber visit within past 12 months and evidence of benefit.NYHA class I‑III

    Coverage duration 12 months

    BENLYSTA SC — Initial/renewal

    Covered when ALL of the following are met for initial therapy in active SLE or lupus nephritis:

    BENLYSTA SC initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For active, autoantibody‑positive systemic lupus erythematosus (SLE) without severe active CNS disease: diagnosis supported by serology (e.g., anti‑double stranded DNA >30 IU/mL, low complement C3/C4, or positive anti‑Smith) and patient will continue standard‑of‑care therapy (antimalarials, corticosteroids, or immunosuppressants) in combination with the requested agent; (3) Inadequate response or medical contraindication to two of the listed standard therapies (hydroxychloroquine, immunosuppressants such as mycophenolate, azathioprine, methotrexate, or oral cyclophosphamide, or oral corticosteroids); (4) For active lupus nephritis: will continue standard‑of‑care and inadequate response or contraindication to mycophenolate mofetil or cyclophosphamide; (5) Not used concurrently with another biologic agent; (6) Prescribed by or in consultation with rheumatologist, nephrologist, or dermatologist as appropriate; (7) Renewal requires positive response and visit within last 14 months.

    Coverage duration 12 months

    BONSITY — Indications/limits

    Covered when ALL of the following are met:

    BONSITY indications and limits: (A) Postmenopausal women with osteoporosis at high fracture risk or with contraindication or inadequate response to one other available osteoporosis therapy (e.g., bisphosphonates); OR (B) Men with osteoporosis at high fracture risk with contraindication or inadequate response to one other available therapy; OR (C) Patients with osteoporosis associated with sustained systemic glucocorticoid therapy at high fracture risk with contraindication or inadequate response to one other therapy. (Additional condition): treatment limited to a total duration of 2 years unless patient remains or returns to high fracture risk.

    Prescribe and monitor per FDA labeling; coverage limited to 2 years unless continued high fracture risk documented.

    Bosentan — PAH criteria

    Covered when ALL of the following are met for Group 1 PAH:

    Bosentan initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For Group 1 pulmonary arterial hypertension (PAH): diagnosis confirmed by right heart catheterization with mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; (3) Baseline liver tests show ALT/AST not >3× ULN and bilirubin not increased ≥2× ULN (patient must not have ALT/AST >3× ULN or bilirubin increase ≥2× ULN); (4) Prescribed by or in consultation with a cardiologist or pulmonologist; (5) Dosing limited to FDA labeling.ALT/AST <=3x ULN; bilirubin <2x ULN; hemodynamic thresholds as specified

    Coverage duration 12 months

    Specialty oncology/metabolic/infec agents — Initial/renewal

    Covered when product‑specific FDA‑approved indication is present and other product‑specific requirements are met:

    Specialty oncology/metabolic/infectious agents initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Where required, genetic or other diagnostic testing completed with results supporting use of the requested agent; (3) Patient does not have FDA‑labeled limitations of use or contraindications to the requested therapy that are not otherwise supported; (4) For certain oncology indications, documentation of prior therapies or line of therapy per product labeling (e.g., prior sorafenib for HCC with cabozantinib/Cabometyx, prior platinum therapy for some agents) or evidence of inadequate response/intolerance to first‑line therapy; (5) Dosing limited to FDA‑labeled dosing and coverage durations per product (commonly six or twelve months).

    Prescriber specialty and prior therapy documentation required where specified; see individual product entries for details.

    CIMZIA — Indications/step therapy

    Covered when ALL of the following are met for labeled autoimmune indications:

    CIMZIA initial criteria: (1) Diagnosis of the specific FDA‑approved indication (psoriatic arthritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, non‑radiographic axial spondyloarthritis with signs of inflammation) not excluded from Part D; (2) Medical contraindication or inadequate response to at least two preferred drugs as specified per indication; (3) Not used concurrently with other biologic therapies; (4) Prescribed by or in consultation with an appropriate specialist (rheumatologist, dermatologist, or gastroenterologist); (5) Dosing limited to FDA labeling.failure or contraindication to at least two preferred drugs

    Renewal requires treatment goals met; coverage duration 12 months

    CIMZIA Initial Therapy

    Covered when ALL of the following apply for the listed indication

    CIMZIA initial (per‑indication): 1) Confirmed diagnosis of the FDA‑approved indication; 2) Documented inadequate response or medical contraindication to at least two preferred therapies listed for the indication; 3) No concurrent use with another biologic therapy; 4) Prescribed by or in consultation with an appropriate specialist; 5) Use limited to FDA‑labeled dosing.at least two preferred drugs

    Applies per‑indication with specific preferred drug lists

    CIMZIA Renewal

    Renewal covered when

    CIMZIA renewal: Treatment goals have been met as documented by the prescriber.

    Coverage duration 12 months

    COSENTYX Initial Therapy

    Covered when ALL of the following apply for the listed indication

    COSENTYX initial criteria: (1) Diagnosis of the specific FDA‑approved indication (e.g., active psoriatic arthritis, ankylosing spondylitis, plaque psoriasis meeting BSA or special‑site criteria, non‑radiographic axial spondyloarthritis with signs of inflammation, enthesitis‑related arthritis, or hidradenitis suppurativa) not excluded from Part D; (2) Documented inadequate response or medical contraindication to the required prior therapies for the indication (e.g., NSAID trial for axial disease; topical/systemic therapies for psoriasis) for the durations specified; (3) Not used concurrently with other biologic therapies; (4) Prescribed by or in consultation with appropriate specialist (dermatologist or rheumatologist); (5) Dosing limited to FDA labeling.varies by indication

    Renewal requires treatment goals met; coverage duration 12 months

    COSENTYX Renewal

    Renewal covered when

    COSENTYX renewal: Treatment goals have been met as documented by the prescriber.

    Coverage duration 12 months

    Dupixent Initial Therapy

    Covered when ALL of the following apply for the indicated condition

    Dupixent initial (general): (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Condition‑specific severity and prior therapy requirements met: for atopic dermatitis: moderate‑to‑severe disease with ≥10% BSA or special‑site involvement and inadequate response or contraindication to one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor; for eosinophilic asthma: pre‑treatment eosinophils ≥150 cells/µL within prior 12 months and inadequate control despite medium/high‑dose inhaled steroid plus at least one other maintenance medication and exacerbation history as specified; (3) Not used concurrently with another monoclonal antibody therapy; (4) Prescribed by or in consultation with appropriate specialist; (5) Dosing limited to FDA labeling.eosinophils >=150 cells/mcL for eosinophilic asthma; BSA >=10% for atopic dermatitis

    Renewal requires evidence of positive response per product guidance

    Dihydroergotamine Initial Therapy

    Covered when ALL of the following apply

    Dihydroergotamine initial: (1) Diagnosis of an FDA‑approved indication for acute migraine headaches with or without aura not excluded from Part D; (2) Documented inadequate response or medical contraindication to two triptan medications (e.g., sumatriptan, naratriptan, rizatriptan); (3) Not used concurrently with another acute migraine agent (triptan, 5‑HT1F agonist, or acute CGRP agent); (4) Prescribed by or in consultation with a neurologist, pain specialist, or headache specialist; (5) Dosing limited to FDA labeling.failure of two triptans

    Renewal requires documented positive response; coverage duration 12 months

    Deferasirox Initial Therapy

    Covered when ALL of the following apply

    Deferasirox initial: (1) Diagnosis of chronic iron overload due to a non‑transfusion dependent thalassemia syndrome with liver iron concentration (LIC) ≥5 mg Fe/g dry weight and serum ferritin >300 mcg/L, OR diagnosis of chronic iron overload due to blood transfusions with serum ferritin >1000 mcg/L; (2) Patient must not have an FDA‑labeled limitation of use or contraindication to deferasirox; (3) Prescribed by or in consultation with a hematologist or oncologist; (4) Dosing limited to FDA labeling; (5) Renewal requires patient seen within past 12 months and documented positive response (e.g., reduction in ferritin/LIC).LIC >=5 mg Fe/g; ferritin thresholds as listed

    Coverage duration 12 months

    Deferiprone Initial Therapy

    Covered when ALL of the following apply

    Deferiprone initial: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For transfusion‑induced iron overload: ANC >1.5 x10^9/L and medical contraindication or inadequate response to prior iron chelation such as deferasirox; (3) For oral solution formulation, documented difficulty swallowing when applicable; (4) Prescribed by or in consultation with a hematologist or oncologist; (5) Dosing limited to FDA labeling; (6) Renewal requires follow‑up within past 12 months and evidence of response (reduced ferritin).ANC >1.5 x10^9/L

    Coverage duration 12 months

    Dalfampridine Initial Therapy

    Covered when ALL of the following apply

    Dalfampridine initial: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Patient is currently able to walk 25 feet and physician attests patient has difficulty walking; (3) Prescribed by or in consultation with a neurologist; (4) Dosing limited to FDA labeling; (5) Renewal requires documented positive response to therapy (improved walking) and follow‑up.able to walk 25 feet

    Initial coverage six months then 12 months if positive response

    Fidaxomicin (Dificid) Initial Therapy

    Covered when ALL of the following apply

    Fidaxomicin initial: (1) Diagnosis of Clostridioides difficile infection (C. difficile); (2) Use limited to FDA‑labeled dosing and duration (10 days); (3) Prescriber documents indication and appropriateness of fidaxomicin over alternatives when applicable.

    Coverage duration 10 days

    Cromolyn Initial Therapy

    Covered when ALL of the following apply

    Cromolyn initial: (1) Diagnosis appropriate for cromolyn and patient has tried and failed one of the following: concurrent H1+H2 antihistamine therapy or antileukotriene therapy; (2) Prescribed by or in consultation with an allergist or specialist; (3) Dosing limited to FDA labeling; (4) Renewal requires documented positive response to therapy.failure of listed prior therapies

    Coverage duration six months then 12 months if positive

    Cystaran Initial Therapy

    Covered when ALL of the following apply

    Cystaran initial: (1) Diagnosis of cystinosis not excluded from Part D; (2) Prescribed by or in consultation with genetics/metabolism or ophthalmology specialist; (3) Dosing limited to FDA‑labeled dosing; (4) Renewal requires documented positive clinical treatment effect (e.g., slit lamp exam findings).

    Coverage duration 12 months

    Cresemba Initial Therapy

    Covered when ALL of the following apply

    Cresemba initial: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For invasive aspergillosis: documented inadequate response or medical contraindication to voriconazole or posaconazole (posaconazole not required for ages 6–12); (3) For invasive mucormycosis: inadequate response or contraindication to posaconazole; (4) Prescribed by or in consultation with infectious disease, transplant, hematology/oncology specialist; (5) Dosing limited to FDA labeling; (6) Renewal requires documented positive response.

    Initial coverage three months then six months if positive response

    Initial criteria for Dupixent (and similar specialty products) and other listed drugs

    Covered when ALL of the following are met for the specified indication (examples below reflect product‑specific criteria as listed):

    General specialty initial requirement: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Condition‑specific clinical thresholds and prior therapy trials or contraindications as required by the product (examples below); (3) Prescribed by or in consultation with the appropriate specialist when specified; (4) Dosing limited to FDA‑labeled guidelines.

    Applies across listed biologic/specialty products

    Atopic dermatitis (example): Moderate‑to‑severe disease with ≥10% BSA or special‑site involvement, intractable pruritus or oozing/cracking/bleeding, and inadequate response or contraindication to one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor.BSA >=10%

    See product‑specific documentation

    Eosinophilic asthma (example): Eosinophilic or oral corticosteroid‑dependent moderate‑to‑severe asthma with pre‑treatment eosinophils ≥150 cells/µL within prior 12 months, inadequate control despite medium/high‑dose inhaled steroid plus at least one other maintenance medication, and documented exacerbation history per criteria.eosinophils >=150 cells/mcL

    See product‑specific entries for renewal and prescriber requirements

    Requests may be denied if the patient has an FDA‑labeled limitation of use or contraindication to the requested therapy. For products with explicit language stating this requirement, coverage is only considered when the documented diagnosis and supporting information demonstrate the drug is appropriate and no labeled limitation/contraindication applies (examples: abiraterone initial criteria require absence of unsupported FDA limitations of use; LYNPARZA and other oncology agents include similar clauses).

    When submitting a Part D prior authorization, include documentation that addresses any FDA‑labeled limitations or contraindications cited by the product entry (e.g., supporting genetic test results for agents that require testing, or documentation that an FDA limitation is supported by NCCN/compendia if that is to be relied upon).

    Several agents explicitly prohibit concurrent use with other targeted or biologic therapies. Examples include armodafinil/modafinil (may not be used concurrently with the other targeted wakefulness agent), and multiple biologics such as BENLYSTA and CIMZIA, which state they may not be used concurrently with another biologic agent for the same therapeutic purpose.

    Prior authorization requests should document current and recent therapies; concurrent use with a disallowed agent is an exclusion and will typically result in denial unless clear documentation supports a permitted exception.

    For bosentan used in Group 1 pulmonary arterial hypertension, therapy is excluded when liver tests exceed safety thresholds. Specifically, do not authorize bosentan if the patient has ALT or AST > 3× ULN or an increase in bilirubin ≥ 2× ULN. Documentation of baseline and recent hepatic laboratory values is required to confirm eligibility.

    Coverage for ATTRUBY (for transthyretin-mediated amyloid cardiomyopathy) requires exclusion of light‑chain amyloidosis. The patient must be documented as negative for light‑chain (AL) amyloidosis (per the diagnostic pathway: cardiac biopsy with ATTR confirmation, or the listed nonbiopsy criteria including serum/urine immunofixation and free light chain testing plus 99mTc‑PYP findings). Requests that do not show negative evaluation for AL amyloidosis will not meet the coverage criteria.

    Initial Therapy — Entry Requirements

    inv-388: Initial therapy examples

    Initial approvals require diagnosis and prior therapy trials where specified.

    Initial therapy examples overview: Providers must document diagnosis of an FDA‑approved indication and any prerequisite trials/failures or contraindications to preferred therapies as specified for each product; specialist consultation and required diagnostic testing (genetic tests, imaging, hemodynamics) must be submitted when required.

    See individual product entries for precise required trials and diagnostic thresholds

    inv-389: Armodafinil initial

    Covered when ALL of the following are met for initial therapy:

    Armodafinil initial specifics: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) OSA diagnosis confirmed per sleep study thresholds (>=15 events/hour, or >=5 events/hour plus qualifying symptoms) unless prescriber documents study not feasible; (3) For shift‑work disorder/narcolepsy, diagnostic testing or prescriber justification provided; (4) Not used concurrently with modafinil; (5) Dosing within FDA labeling; (6) Renewal requires documented positive response.OSA diagnostic thresholds as specified

    Coverage duration six months then 12 months if renewed

    inv-390: ATTRUBY initial

    Covered when ALL of the following are met for initial therapy:

    ATTRUBY initial specifics: (1) Diagnosis of ATTR‑CM with required diagnostic confirmation (cardiac biopsy with ATTR confirmation OR negative monoclonal protein testing plus 99mTc‑PYP uptake >1.5 or grade ≥2); (2) Clinical HF history and NYHA class I–III; (3) Negative for light‑chain amyloidosis; (4) Prescribed by/with cardiology consultation; (5) Renewal: seen within past 12 months and demonstrated efficacy.NYHA I‑III

    Coverage duration 12 months

    inv-391: Initial Therapy Requirements (summary)

    Initial therapy requirements vary by drug but consistently require diagnosis and prior trial/failure or contraindication to specified therapies

    Initial therapy requirements (summary): For each listed product, initial coverage requires: (A) diagnosis of an FDA‑approved indication not excluded from Part D; (B) documentation of prerequisite therapy trials, inadequate responses, or contraindications as specified per product; (C) required diagnostic testing (genetic tests, imaging, hemodynamics) when indicated; (D) prescriber specialty or consultation when specified; (E) dosing limited to FDA‑labeled guidelines.varies by product

    Providers must submit supporting documentation per product

    inv-392: Initial therapy rules

    Initial therapy is authorized when the product‑specific clinical entry requirements and prerequisite therapy failures or contraindications are documented.

    Initial therapy rule: Documented diagnosis of an FDA‑approved indication and evidence of required prior therapy failures or contraindications, plus specialist consultation or diagnostic testing when specified.

    Applies across listed specialty products

    inv-395: INCRELEX - Initial criteria

    Covered when ALL of the following are met

    INCRELEX initial: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For severe primary IGF‑1 deficiency or GH gene deletion with neutralizing antibodies to GH: height SDS ≤‑3.0 and basal IGF‑1 SDS ≤‑3.0; (3) Prescribed by or in consultation with an endocrinologist; (4) Dosing limited to FDA labeling; (5) Renewal requires documented positive response.height SDS <= -3.0; basal IGF-1 SDS <= -3.0

    Coverage duration 12 months

    inv-394: Inqovi initial

    Covered when ALL of the following are met:

    Inqovi initial: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) Genetic testing completed if required with supportive results; (3) Patient does not have FDA‑labeled limitations of use not supported by NCCN; (4) Requested agent is FDA‑labeled or compendia‑supported for the indication, OR patient currently or previously received and benefited from the medication; (5) For MDS: inadequate response or contraindication to azacitidine when indicated; (6) Dosing limited to FDA labeling; (7) Renewal requires documented positive response.

    Coverage duration six months

    inv-396: Initial therapy examples

    Examples of initial therapy requirements

    Severe asthma initial (biologics example): Pre‑treatment eosinophil count ≥150 cells/µL within the prior 12 months, inadequate control despite medium/high‑dose inhaled corticosteroid plus at least one other maintenance medication, and defined exacerbation history (systemic steroid courses or hospitalization/ER visits) as specified.eosinophils >=150 cells/mcL

    Prescriber specialty required; renewal requires evidence of clinical benefit

    inv-397: OFEV initial

    Nintedanib (OFEV) criteria

    OFEV initial for IPF: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; (2) For idiopathic pulmonary fibrosis (IPF): exclusion of other known causes of ILD, HRCT pattern consistent with usual interstitial pneumonia (UIP) or supportive combinations of HRCT and histopathology, baseline FVC ≥50% and %DLCO ≥30%; (3) Must not have underlying liver disease; (4) Prescribed by or in consultation with a pulmonologist or rheumatologist; (5) Dosing limited to FDA labeling; (6) Renewal requires evidence of positive response and recent follow‑up.FVC >=50%; %DLCO >=30%

    Coverage duration 12 months

    Renewal and Continuation — Evidence of Benefit

    inv-405: Renewal requirements

    Renewal generally requires evidence of benefit or positive response.

    General renewal: For continued coverage, providers must document clinical benefit (e.g., reduced exacerbations, symptomatic improvement, objective test improvement) and, where specified, that the patient has been seen within the product's required follow‑up interval (commonly within the past 12 months).

    Specific renewal criteria are product‑dependent

    inv-406: Renewal examples

    Renewal/continuation requirements (examples):

    Armodafinil renewal example: Positive response to therapy documented by the prescriber; follow‑up visit within the required interval per product policy.
    ATTRUBY renewal example: Seen by prescriber within past 12 months and documentation of continued efficacy and NYHA class within I–III.
    BENLYSTA renewal example: Positive response to therapy and patient seen within last 14 months documented.
    CAYSTON renewal example: Patient seen within last 12 months and positive response to therapy documented.

    Step Therapy / Prerequisite Trials

    Step therapy requirementExamples / affected productsRequired documentation
    Trial and failure of preferred agents required prior to approval
    Actemra: inadequate response or contraindication to at least two preferred drugs (examples: Hadlima, Simlandi, Rinvoq); many biologics/JAK inhibitors: prior trials of listed preferred drugs
    Document prior trials and reason for inadequate response or contraindication; prescriber specialty/consultation as specified (e.g., rheumatologist or pulmonologist for Actemra)
    Step therapy requirementExamples / affected productsRequired documentation
    Trial of two preferred drugs required prior to coverage
    Antiseizure and some antidepressant agents: inadequate response or contraindication to two alternatives (examples listed include several antipsychotics/antiseizure/antidepressant therapies)
    Document trials of two specified preferred agents with durations and reasons for failure or contraindication; specialist prescriber notation when required
    Prerequisite therapyRequirement detailsCoverage threshold / duration
    High-intensity statin + ezetimibe trial
    Trial of one high-intensity statin concomitantly with ezetimibe for a minimum of 8 weeks, or documented statin intolerance to atorvastatin and rosuvastatin
    Used when LDL remains >70 mg/dL after the 8-week trial; coverage duration 12 months; dosing limited to FDA labeling
    Prerequisite therapyRequirement detailsCoverage / exclusions
    High-intensity statin + ezetimibe trial (or documented statin intolerance)
    Trial of one high-intensity statin plus ezetimibe for 8 weeks with LDL remaining above goal, or documented statin intolerance (rhabdomyolysis to one statin or intolerance to both atorvastatin and rosuvastatin)
    Required for Repatha approval for HeFH/ASCVD; Repatha may not be used concurrently with Praluent or Leqvio; coverage duration 12 months; dosing limited to FDA labeling
    Requirement typeExamples / affected agentsNotes / documentation
    Trial and failure or contraindication to specified prior therapies required
    CIMZIA, Stelara, many JAK/biologic agents, Nurtec, Kisqali and other products — specific lists of preferred drugs or prior therapies are provided per indication (e.g., CIMZIA: failure/inadequate response to at least two preferred drugs)
    Providers must document prior therapies tried, durations, and reason for inadequacy or contraindication; genetic testing results when required for oncology agents; prescriber specialty as specified
    Prerequisite therapy required?Requirement detailsDocumentation / duration
    Yes
    VUMERITY requires inadequate response or contraindication to one listed disease-modifying therapy (teriflunomide, dimethyl fumarate, fingolimod, or glatiramer acetate)
    Document trial and inadequate response or contraindication to at least one listed DMT; coverage duration 12 months; dosing limited to FDA labeling
    Prerequisite therapy required?Requirement detailsDocumentation / duration
    Yes
    VERQUVO requires inadequate response or contraindication to at least two guideline-directed heart failure therapies (ACE/ARB/ARNI, beta-blocker, aldosterone antagonist, or SGLT2 inhibitor) and additional clinical criteria (EF <45%, NYHA II–IV, recent HF hospitalization or outpatient IV diuretics)
    Document EF <45%, NYHA class II–IV, prior HF hospitalization within 6 months or outpatient IV diuretic within 3 months, and trials/intolerance to listed guideline therapies; coverage duration 12 months; cardiology prescriber or consult recommended
    Prerequisite therapy required?Requirement detailsDocumentation / exclusions
    Yes
    XELJANZ requires inadequate response or contraindication to at least two preferred drugs for the specific indication (PsA, RA, UC, polyarticular JIA, AS)
    Document trials of at least two preferred agents and reasons for failure or contraindication; XELJANZ must not be used concurrently with other biologic therapies; prescriber specialist consultation required; coverage duration 12 months

    Formulary and Product Coding

    Formulary referencemixed
    FID: 26132HealthPartners Part D Formulary identifier
    Listed products in this document portionmixed
    CIMZIACIMZIA; CIMZIA POWDER FOR RECONST; CIMZIA STARTER KIT
    COSENTYXCOSENTYX (2 SYRINGES); COSENTYX PEN; COSENTYX PEN (2 PENS); COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML; COSENTYX UNOREADY PEN
    DUPIXENTDUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML; DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML
    Other listed drugsmixed
    deferasiroxdeferasirox
    deferipronedeferiprone
    fidaxomicinDIFICID ORAL SUSPENSION FOR RECONSTITUTION; fidaxomicin
    Formulary Identifiermixed
    FID: 26132HealthPartners Part D Formulary identifier referenced for multiple products
    Imbruvica productsNDC/label
    IMBRUVICA ORAL CAPSULE 140 MGIMBRUVICA ORAL CAPSULE 140 MG
    IMBRUVICA ORAL CAPSULE 70 MGIMBRUVICA ORAL CAPSULE 70 MG
    IMBRUVICA ORAL SUSPENSIONIMBRUVICA ORAL SUSPENSION
    IMBRUVICA ORAL TABLET 140 MGIMBRUVICA ORAL TABLET 140 MG
    IMBRUVICA ORAL TABLET 280 MGIMBRUVICA ORAL TABLET 280 MG
    IMBRUVICA ORAL TABLET 420 MGIMBRUVICA ORAL TABLET 420 MG
    InbrijaNDC/label
    INBRIJA INHALATION CAPSULEINBRIJA INHALATION CAPSULE, W/INHALATION DEVICE
    Ancillary insulin delivery itemsNDC/label
    alcohol padsalcohol pads
    NOVO PEN NEEDLENOVO PEN NEEDLE
    GAUZE PADS 2 X 2GAUZE PADS 2 X 2
    EMBECTA INSULIN SYRINGEEMBECTA INSULIN SYRINGE
    EMBECTA PEN NEEDLEEMBECTA PEN NEEDLE
    KerendiaNDC/label
    KERENDIAKERENDIA
    KesimptaNDC/label
    KESIMPTA PENKESIMPTA PEN
    KineretNDC/label
    KINERETKINERET
    Kisqali productsNDC/label
    KISQALI FEMARA CO-PACKKISQALI FEMARA CO-PACK ORAL TABLET
    KISQALIKISQALI ORAL TABLET
    Topical and linezolid productsNDC/label
    lidocaine topical adhesive patch, medicated 5%lidocaine topical adhesive patch,medicated 5 %
    linezolidlinezolid
    linezolid in dextrose 5%linezolid in dextrose 5%
    LINEZOLID-0.9% SODIUM CHLORIDELINEZOLID-0.9% SODIUM CHLORIDE
    LivtencityNDC/label
    LIVTENCITYLIVTENCITY
    AlosetronNDC/label
    alosetronalosetron
    VENCLEXTA productsNDC|product
    VENCLEXTA ORAL TABLET 10 MGproduct listed in formulary entry
    VENCLEXTA ORAL TABLET 50 MGproduct listed in formulary entry
    VENCLEXTA ORAL TABLET 100 MGproduct listed in formulary entry
    VENCLEXTA STARTING PACKproduct listed in formulary entry
    XALKORI productsNDC|product
    XALKORI ORAL CAPSULEformulary product
    XALKORI ORAL PELLET 150 MG, 20formulary product

    Provider Actions — Prior Authorization & Documentation

    Prior Authorization

    Product-specific prior authorization required

    Prior authorization is required for Part D drugs listed in this section; initial and renewal clinical criteria are specified per product and commonly include confirmation of an FDA‑approved diagnosis, required prior therapy trials or documented contraindications, relevant diagnostic or lab testing, and prescriber specialty when applicable.

    • PA applied per product-specific entry (see product sections for exact initial/renewal requirements and documentation).
    • Coverage durations are specified per product (commonly 6 or 12 months).
    Prior Authorization

    PA requires documented trials or contraindications to preferred therapies

    Prior authorization approvals require submitted documentation of the diagnosis and evidence of inadequate response to—or contraindication for—specified preferred therapies when step requirements apply (number of required trials varies by indication).

    • Document which preferred agents were tried, treatment durations, and reason for failure or intolerance.
    • If product requires two preferred-drug failures, provide records showing trials of two listed alternatives.
    Prior Authorization

    PA required for listed specialty drugs with indication‑specific criteria

    Prior authorization is required for the specialty drugs listed; initial approval requires meeting the indication‑specific entry criteria (FDA‑approved diagnosis, required lab/genetic testing if specified, not excluded from Part D) and submission of the supporting clinical documentation noted in each product section.

    • Examples: oncology, CFTR modulators, biologics, PAH agents and other listed specialty products require indication‑specific documentation.
    • Follow the product entry for required prescriber specialty and dosing limits.
    Prior Authorization

    Prior authorization per HealthPartners Part D Formulary (FID: 26132)

    These Part D drugs require prior authorization per the HealthPartners Part D Formulary (FID: 26132); PA criteria are applied to FDA‑approved indications and product‑specific rules listed in the formulary.

    • When submitting a PA, reference Formulary FID: 26132 to ensure the request aligns with the formulary entry and applicable PA rules.
    Prior Authorization

    PA applies to initial and renewal requests; durations vary

    Initial and renewal prior authorization requirements apply for listed Part D drugs; coverage durations are specified per product (commonly 6 months for many oncology/short-course agents and 12 months for chronic biologic or maintenance therapies).

    • Review the product entry for the exact initial duration (examples: abiraterone 6 months, many biologics 12 months).
    • Renewal typically requires evidence of clinical benefit and recent prescriber follow‑up.
    Documentation Required

    Initial PA documentation required (example: abiraterone)

    For new starts submit documentation of the FDA‑approved diagnosis, required genetic testing results when indicated, absence of unsupported FDA‑labeled limitations of use, and prior therapy details showing trials/failures or that the patient previously benefited from the agent where applicable (example: abiraterone).

    • Abiraterone initial PA: diagnosis of an FDA‑approved indication, genetic testing if required, no unsupported FDA limitations, and dosing limited to FDA labeling; coverage duration six months.
    • Provide rationale if requesting a non‑preferred strength/formulation (e.g., abiraterone 500 mg vs 250 mg tablet).
    Documentation Required

    Include right heart catheterization hemodynamics for PAH agents

    For PA requests for pulmonary arterial hypertension agents, include right heart catheterization data documenting hemodynamics (mean PAP, PCWP, PVR) that meet the PAH criteria when required by the product entry.

    • Right heart cath thresholds in entries: mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 (or ≥3) Wood units as specified by the product.
    • Prescriber specialty (cardiology or pulmonology) is typically required.
    Documentation Required

    Submit use/setting details when Part B vs Part D determination may apply

    When a drug may be covered under Part B or Part D depending on setting or use, submit information describing the intended use and dispensing setting so HealthPartners can determine the appropriate benefit and process the PA accordingly.

    • Examples: some immunoglobulins, Retacrit, and certain injectables may require setting details (infusion center, outpatient hospital, home) to assign Part B vs Part D coverage.
    • Provide documentation of the administration site and clinical rationale for outpatient drug vs physician‑administered benefit.
    Denial Risk

    Denial risk — FDA‑labeled limitations of use or contraindications

    Requests will be denied if the patient has an FDA‑labeled limitation of use or a contraindication to the requested therapy when the product entry explicitly states the patient must not have such limitations.

    • Confirm the patient does not meet any FDA‑labeled exclusion (e.g., abiraterone entries require absence of unsupported labeled limitations).
    • If an FDA contraindication exists, do not submit a PA unless documentation shows the contraindication does not apply and is supported by guidelines.
    Denial Risk

    Denial risk — concurrent disallowed or interacting therapies

    Therapy may be denied if requested concurrently with another product that the formulary explicitly prohibits for simultaneous use (e.g., concurrent biologic/monoclonal antibody therapies, CFTR modulators, or interacting antivirals).

    • Examples: CIMZIA, COSENTYX, DUPIXENT, and other biologics may not be used concurrently with another biologic; Livtencity may not be used with ganciclovir/valganciclovir/foscarnet/cidofovir.
    • Arm providers must document discontinuation of excluded concurrent agents before PA approval.
    Denial Risk

    Common denial triggers — missing tests, contraindications, or concurrent disallowed therapy

    Common denial triggers include failure to meet initial criteria (missing required genetic testing or diagnostic confirmation when specified), presence of an FDA‑labeled limitation/contraindication, or documentation of concurrent prohibited therapies.

    • Ensure required tests (genetic, hemodynamic, eosinophil counts, HCV RNA, etc.) are attached when indicated.
    • Document prior therapy trials and objective evidence of inadequate response or intolerance as specified in the product section to avoid denial.

    Quantity and Dosing Limits

    GATTEX — quantity/dose reference
    GATTEX dose0.05 mg/kg per day (FDA‑approved dosing)
    Indication prerequisiteShort bowel syndrome with ≥1 year dependence on parenteral nutrition
    Prescriber restrictionPrescribed by or in consultation with a gastroenterologist
    Coverage duration12 months
    Quantity/dose limit noteDose limited to the FDA‑approved dose of 0.05 mg/kg per day
    Valchlor — approval/tube limit reference
    Valchlor tube limitApprovals limited to a quantity of two 60 gram tubes per month
    Prior therapy requiredPatient must have received at least one prior skin‑directed therapy (e.g., topical corticosteroids, bexarotene topical gel)
    Initial duration6 months (initial), then 12 months if renewal criteria met
    Prescriber restrictionNone specified in entry
    XIFAXAN — dosing for indicated uses (550 mg three times daily)
    XIFAXAN dosing (indicated uses)550 mg three times daily
    IBS‑D limitationDose limited to 550 mg three times daily for 14 days (IBS‑D) with retreatment restrictions
    Travelers' diarrhea duration3 days (travelers' diarrhea)
    Hepatic encephalopathy duration12 months (coverage duration for HE indication)
    ZEJULA — per FDA-labeled dosing
    ZEJULA dosingPer FDA‑labeled dosing
    Typical coverage duration6 months (initial) per product entry
    Indication examplesFirst‑line maintenance of advanced ovarian/fallopian/primary peritoneal cancer in response to platinum‑based chemotherapy; maintenance for deleterious germline BRCA‑mutated recurrent disease
    LimitationPatient must not have an FDA‑labeled limitation of use or contraindication to therapy

    Site-of-Care Determinations (Part B vs Part D)

    Note
    Note
    Note
    Note

    Clinical Definitions and Diagnostic Thresholds

    Right heart catheterization parameters for PAH — Mean PAP, PCWP, PVR thresholds.
    Mean pulmonary artery pressure (mPAP)>= 20 mmHg
    Pulmonary capillary wedge pressure (PCWP)<= 15 mmHg
    Pulmonary vascular resistance (PVR)> 2 Wood units
    ContextValues required from right heart catheterization to confirm Group 1 PAH for PA therapies
    Testosterone deficiency threshold — Documented testosterone level < 300 ng/dL for approval of testosterone replacement products.
    Testosterone deficiency thresholdDocumented total testosterone level < 300 ng/dL
    Indication requirementDiagnosis of an FDA‑approved indication not excluded from Part D
    Coverage duration12 months
    OSA diagnostic criteria — ≥15 events/hour or ≥5 with symptoms.
    OSA diagnostic criterion — events/hour>= 15 obstructive respiratory events per hour on sleep study
    Alternative OSA criterion>= 5 obstructive events/hour PLUS at least one qualifying symptom (daytime sleepiness, unintentional sleep episodes, unrefreshing sleep, fatigue, insomnia, gasping/choking, loud snoring, or breathing interruptions)
    Documentation noteSleep study confirmation required unless prescriber documents study is not feasible
    HAE confirmation testing — C1-INH antigenic/function and C4 levels or known mutation.
    HAE confirmatory testsC1‑INH antigenic level, C1‑INH functional level, and C4 level
    Genetic confirmationOr known HAE‑causing mutation (e.g., factor XII, ANGPT1, PLG, KNG1, 3‑O‑sulfotransferase 6, MYOFERLIN)
    Clinical contextRequired to confirm diagnosis for prophylaxis or acute HAE treatment prior to PA
    CFTR mutation responsive — In vitro assay demonstration for CFTR modulator responsiveness.
    CFTR modulator responsivenessCFTR gene mutation demonstrated by in vitro assay data to be responsive to the prescribed CFTR modulator
    Genotype restriction exampleKalydeco entry: patient must not be homozygous for F508del when requiring in‑vitro responsive mutation
    Prescriber restrictionPrescribed by or in consultation with a CF specialist or pulmonologist
    06/01/2026 — Formulary effective date included in document header.
    Formulary effective date06/01/2026
    Formulary identifierHealthPartners Part D Formulary (FID: 26132)
    Document typePart D formulary / prior authorization index entries — effective date shown in header

    Background and Scope

    This section of the Part D prior‑authorization document summarizes the clinical prerequisites used to determine medical necessity for specialty and other outpatient drugs covered under HealthPartners Part D. Criteria emphasize that coverage is limited to FDA‑approved indications (unless otherwise supported by compendia), that prescribed dosing must be within FDA‑labeled dosing, and that prior authorization requires submission of the diagnosis and supporting clinical documentation (for example, genetic testing when required, baseline labs, prior therapy trials, or procedure results).

    The rules also outline common exclusion and denial triggers — for example, presence of an FDA‑labeled limitation of use or contraindication, or concurrent use of prohibited therapies — and describe typical PA administrative expectations such as prescriber specialty requirements and coverage durations (commonly 6 or 12 months depending on the product).

    Revision History

    06/01/2026effective_dateLatest

    HealthPartners Part D Formulary (FID: 26132) effective date for this document extract